Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Creative Commons License

Pittock S. J., Berthele A., Fujihara K., Kim H. J., Levy M., Palace J., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.381, sa.7, ss.614-625, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 381 Sayı: 7
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1056/nejmoa1900866
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.614-625
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Neuromyelitis optica spectrum disorder is a relapsing inflammatory disorder of the central nervous system. Two thirds of patients have antibodies against aquaporin-4, and CNS damage is complement dependent. The inhibitor of terminal complement C5 cleavage, eculizumab, reduced relapses of NMOSD.